ID   DGKQ_HUMAN              Reviewed;         942 AA.
AC   P52824; Q6P3W4;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-SEP-2009, sequence version 2.
DT   10-MAY-2017, entry version 144.
DE   RecName: Full=Diacylglycerol kinase theta;
DE            Short=DAG kinase theta;
DE            EC=2.7.1.107;
DE   AltName: Full=Diglyceride kinase theta;
DE            Short=DGK-theta;
GN   Name=DGKQ; Synonyms=DAGK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=7607687; DOI=10.1016/0888-7543(95)80182-L;
RA   Pilz A., Schaap D., Hunt D., Fitzgibbon J.;
RT   "Chromosomal localization of three mouse diacylglycerol kinase (DAGK)
RT   genes: genes sharing sequence homology to the Drosophila retinal
RT   degeneration A (rdgA) gene.";
RL   Genomics 26:599-601(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LEU-27.
RC   TISSUE=Uterus;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   CATALYTIC ACTIVITY, INTERACTION WITH RHOA, AND SUBCELLULAR LOCATION.
RX   PubMed=10066731; DOI=10.1074/jbc.274.11.6820;
RA   Houssa B., de Widt J., Kranenburg O., Moolenaar W.H.,
RA   van Blitterswijk W.J.;
RT   "Diacylglycerol kinase theta binds to and is negatively regulated by
RT   active RhoA.";
RL   J. Biol. Chem. 274:6820-6822(1999).
RN   [5]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH PLCB1.
RX   PubMed=12799190; DOI=10.1016/S0014-4827(03)00115-0;
RA   Tabellini G., Bortul R., Santi S., Riccio M., Baldini G.,
RA   Cappellini A., Billi A.M., Berezney R., Ruggeri A., Cocco L.,
RA   Martelli A.M.;
RT   "Diacylglycerol kinase-theta is localized in the speckle domains of
RT   the nucleus.";
RL   Exp. Cell Res. 287:143-154(2003).
RN   [6]
RP   INTERACTION WITH RHOA, AND MUTAGENESIS OF GLY-237; PRO-245 AND
RP   PRO-246.
RX   PubMed=15164764; DOI=10.1016/j.bbalip.2003.11.008;
RA   Los A.P., van Baal J., de Widt J., Divecha N., van Blitterswijk W.J.;
RT   "Structure-activity relationship of diacylglycerol kinase theta.";
RL   Biochim. Biophys. Acta 1636:169-174(2004).
RN   [7]
RP   INTERACTION WITH PRKCE AND PRKCH, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF CYS-100; CYS-160; CYS-226 AND GLY-237.
RX   PubMed=15632189; DOI=10.1074/jbc.M409301200;
RA   van Baal J., de Widt J., Divecha N., van Blitterswijk W.J.;
RT   "Translocation of diacylglycerol kinase theta from cytosol to plasma
RT   membrane in response to activation of G protein-coupled receptors and
RT   protein kinase C.";
RL   J. Biol. Chem. 280:9870-9878(2005).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH NR5A1.
RX   PubMed=17664281; DOI=10.1128/MCB.00355-07;
RA   Li D., Urs A.N., Allegood J., Leon A., Merrill A.H. Jr., Sewer M.B.;
RT   "Cyclic AMP-stimulated interaction between steroidogenic factor 1 and
RT   diacylglycerol kinase theta facilitates induction of CYP17.";
RL   Mol. Cell. Biol. 27:6669-6685(2007).
CC   -!- FUNCTION: Phosphorylates diacylglycerol (DAG) to generate
CC       phosphatidic acid (PA). May regulate the activity of protein
CC       kinase C by controlling the balance between these two signaling
CC       lipids. Activated in the nucleus in response to alpha-thrombin and
CC       nerve growth factor (By similarity). May be involved in cAMP-
CC       induced activation of NR5A1 and subsequent steroidogenic gene
CC       transcription by delivering PA as ligand for NR5A1. Acts
CC       synergistically with NR5A1 on CYP17 transcriptional activity.
CC       {ECO:0000250, ECO:0000269|PubMed:17664281}.
CC   -!- CATALYTIC ACTIVITY: ATP + 1,2-diacyl-sn-glycerol = ADP + 1,2-
CC       diacyl-sn-glycerol 3-phosphate. {ECO:0000269|PubMed:10066731}.
CC   -!- ENZYME REGULATION: Inactivated by binding to RHOA. Not inhibited
CC       by phosphatidylserine.
CC   -!- SUBUNIT: Interacts with RHOA (constitutively activated, GTP-
CC       bound); the interaction inhibits DGKQ. Interacts with PRKCE.
CC       Interacts with PRKCH. Interacts with PLCB1. Interacts with NR5A1;
CC       the interaction requires the LXXLL motif 1 and LXXLL motif 2 in
CC       DGKQ. {ECO:0000269|PubMed:10066731, ECO:0000269|PubMed:12799190,
CC       ECO:0000269|PubMed:15164764, ECO:0000269|PubMed:15632189,
CC       ECO:0000269|PubMed:17664281}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:15632189}.
CC       Cell membrane {ECO:0000269|PubMed:10066731,
CC       ECO:0000269|PubMed:15632189}. Cytoplasm, cytoskeleton
CC       {ECO:0000269|PubMed:10066731}. Nucleus
CC       {ECO:0000269|PubMed:12799190}. Nucleus speckle
CC       {ECO:0000269|PubMed:12799190}. Note=Translocates to the nucleus in
CC       response to thrombin stimulation (PubMed:15632189). Translocates
CC       to the plasma membrane in response to steroid hormone receptor
CC       stimulation (PubMed:15632189). Translocation to the plasma
CC       membrane is dependent on G-protein coupled receptor stimulation
CC       and subsequent activation of PRKCE and probably PRKCH
CC       (PubMed:15632189).
CC   -!- DOMAIN: The L-X-X-L-L repeats are implicated in binding to the
CC       nuclear receptor NR5A1.
CC   -!- PTM: Phosphorylated by PRKCE and PRKCH in vitro.
CC   -!- SIMILARITY: Belongs to the eukaryotic diacylglycerol kinase
CC       family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L38707; AAA98749.1; -; mRNA.
DR   EMBL; AC019103; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC063801; AAH63801.1; -; mRNA.
DR   CCDS; CCDS3342.1; -.
DR   RefSeq; NP_001338.2; NM_001347.3.
DR   UniGene; Hs.584858; -.
DR   ProteinModelPortal; P52824; -.
DR   BioGrid; 107979; 9.
DR   IntAct; P52824; 1.
DR   STRING; 9606.ENSP00000273814; -.
DR   SwissLipids; SLP:000000740; -.
DR   iPTMnet; P52824; -.
DR   PhosphoSitePlus; P52824; -.
DR   BioMuta; DGKQ; -.
DR   DMDM; 257051005; -.
DR   EPD; P52824; -.
DR   MaxQB; P52824; -.
DR   PaxDb; P52824; -.
DR   PeptideAtlas; P52824; -.
DR   PRIDE; P52824; -.
DR   DNASU; 1609; -.
DR   Ensembl; ENST00000273814; ENSP00000273814; ENSG00000145214.
DR   GeneID; 1609; -.
DR   KEGG; hsa:1609; -.
DR   UCSC; uc003gbw.5; human.
DR   CTD; 1609; -.
DR   DisGeNET; 1609; -.
DR   GeneCards; DGKQ; -.
DR   HGNC; HGNC:2856; DGKQ.
DR   HPA; CAB033835; -.
DR   HPA; HPA026797; -.
DR   MIM; 601207; gene.
DR   neXtProt; NX_P52824; -.
DR   OpenTargets; ENSG00000145214; -.
DR   PharmGKB; PA27317; -.
DR   eggNOG; KOG1169; Eukaryota.
DR   eggNOG; ENOG410XQVB; LUCA.
DR   GeneTree; ENSGT00760000119050; -.
DR   HOGENOM; HOG000007900; -.
DR   HOVERGEN; HBG094675; -.
DR   InParanoid; P52824; -.
DR   KO; K00901; -.
DR   OMA; TKPTFCH; -.
DR   OrthoDB; EOG091G02NN; -.
DR   PhylomeDB; P52824; -.
DR   TreeFam; TF312817; -.
DR   Reactome; R-HSA-114508; Effects of PIP2 hydrolysis.
DR   GeneWiki; DGKQ; -.
DR   GenomeRNAi; 1609; -.
DR   PRO; PR:P52824; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   Bgee; ENSG00000145214; -.
DR   CleanEx; HS_DGKQ; -.
DR   ExpressionAtlas; P52824; baseline and differential.
DR   Genevisible; P52824; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005768; C:endosome; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0016363; C:nuclear matrix; ISS:ParkinsonsUK-UCL.
DR   GO; GO:0016607; C:nuclear speck; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0012506; C:vesicle membrane; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0033613; F:activating transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004143; F:diacylglycerol kinase activity; IDA:UniProtKB.
DR   GO; GO:0019900; F:kinase binding; IPI:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003951; F:NAD+ kinase activity; IEA:InterPro.
DR   GO; GO:0043274; F:phospholipase binding; IPI:UniProtKB.
DR   GO; GO:0030297; F:transmembrane receptor protein tyrosine kinase activator activity; IGI:ParkinsonsUK-UCL.
DR   GO; GO:0019933; P:cAMP-mediated signaling; IDA:UniProtKB.
DR   GO; GO:0046339; P:diacylglycerol metabolic process; IDA:BHF-UCL.
DR   GO; GO:0007186; P:G-protein coupled receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0046486; P:glycerolipid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0046834; P:lipid phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0010801; P:negative regulation of peptidyl-threonine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006654; P:phosphatidic acid biosynthetic process; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0050731; P:positive regulation of peptidyl-tyrosine phosphorylation; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0070528; P:protein kinase C signaling; IDA:UniProtKB.
DR   GO; GO:0007205; P:protein kinase C-activating G-protein coupled receptor signaling pathway; IEA:InterPro.
DR   GO; GO:0090181; P:regulation of cholesterol metabolic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:2000064; P:regulation of cortisol biosynthetic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0008277; P:regulation of G-protein coupled receptor protein signaling pathway; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0006111; P:regulation of gluconeogenesis; IMP:ParkinsonsUK-UCL.
DR   GO; GO:2000182; P:regulation of progesterone biosynthetic process; IMP:ParkinsonsUK-UCL.
DR   GO; GO:1903432; P:regulation of TORC1 signaling; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006357; P:regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0033198; P:response to ATP; IDA:UniProtKB.
DR   GO; GO:0051591; P:response to cAMP; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0070493; P:thrombin-activated receptor signaling pathway; IDA:UniProtKB.
DR   CDD; cd00029; C1; 2.
DR   Gene3D; 3.40.50.10330; -; 1.
DR   InterPro; IPR017438; ATP-NAD_kinase_dom_1.
DR   InterPro; IPR000756; Diacylglycerol_kin_accessory.
DR   InterPro; IPR001206; Diacylglycerol_kinase_cat_dom.
DR   InterPro; IPR016064; NAD/diacylglycerol_kinase.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR000159; RA_dom.
DR   InterPro; IPR029071; Ubiquitin-rel_dom.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00609; DAGK_acc; 1.
DR   Pfam; PF00781; DAGK_cat; 1.
DR   Pfam; PF00788; RA; 1.
DR   SMART; SM00109; C1; 3.
DR   SMART; SM00045; DAGKa; 1.
DR   SMART; SM00046; DAGKc; 1.
DR   SMART; SM00314; RA; 1.
DR   SUPFAM; SSF111331; SSF111331; 1.
DR   SUPFAM; SSF54236; SSF54236; 1.
DR   PROSITE; PS50146; DAGK; 1.
DR   PROSITE; PS50200; RA; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 3.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 3.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell membrane; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Kinase; Membrane; Metal-binding; Nucleotide-binding;
KW   Nucleus; Phosphoprotein; Polymorphism; Reference proteome; Repeat;
KW   Transferase; Zinc; Zinc-finger.
FT   CHAIN         1    942       Diacylglycerol kinase theta.
FT                                /FTId=PRO_0000218467.
FT   DOMAIN      395    494       Ras-associating. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00166}.
FT   DOMAIN      584    721       DAGKc. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00783}.
FT   ZN_FING      60    108       Phorbol-ester/DAG-type 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   ZN_FING     121    168       Phorbol-ester/DAG-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   ZN_FING     183    234       Phorbol-ester/DAG-type 3.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   MOTIF       555    559       LXXLL motif 1.
FT   MOTIF       574    578       LXXLL motif 2.
FT   MOD_RES      22     22       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6P5E8}.
FT   MOD_RES      26     26       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q6P5E8}.
FT   VARIANT      27     27       P -> L (in dbSNP:rs17855876).
FT                                {ECO:0000269|PubMed:15489334}.
FT                                /FTId=VAR_058478.
FT   MUTAGEN     100    100       C->G: Abolishes translocation to the
FT                                plasma membrane.
FT                                {ECO:0000269|PubMed:15632189}.
FT   MUTAGEN     160    160       C->G: Abolishes translocation to the
FT                                plasma membrane.
FT                                {ECO:0000269|PubMed:15632189}.
FT   MUTAGEN     226    226       C->G: Abolishes translocation to the
FT                                plasma membrane.
FT                                {ECO:0000269|PubMed:15632189}.
FT   MUTAGEN     237    237       G->R: Abolishes enzymatic activity; no
FT                                effect on translocation to the plasma
FT                                membrane. {ECO:0000269|PubMed:15164764,
FT                                ECO:0000269|PubMed:15632189}.
FT   MUTAGEN     245    245       P->A,L: Greatly reduces enzymatic
FT                                activity. {ECO:0000269|PubMed:15164764}.
FT   MUTAGEN     246    246       P->L: Abolishes enzymatic activity.
FT                                {ECO:0000269|PubMed:15164764}.
FT   CONFLICT     45     46       PE -> RD (in Ref. 1; AAA98749).
FT                                {ECO:0000305}.
FT   CONFLICT     50     56       VRAPGPA -> GVRARAR (in Ref. 1; AAA98749).
FT                                {ECO:0000305}.
FT   CONFLICT    933    933       A -> R (in Ref. 1; AAA98749).
FT                                {ECO:0000305}.
SQ   SEQUENCE   942 AA;  101155 MW;  836D4FCBC208A5B6 CRC64;
     MAAAAEPGAR AWLGGGSPRP GSPACSPVLG SGGRARPGPG PGPGPERAGV RAPGPAAAPG
     HSFRKVTLTK PTFCHLCSDF IWGLAGFLCD VCNFMSHEKC LKHVRIPCTS VAPSLVRVPV
     AHCFGPRGLH KRKFCAVCRK VLEAPALHCE VCELHLHPDC VPFACSDCRQ CHQDGHQDHD
     THHHHWREGN LPSGARCEVC RKTCGSSDVL AGVRCEWCGV QAHSLCSAAL APECGFGRLR
     SLVLPPACVR LLPGGFSKTQ SFRIVEAAEP GEGGDGADGS AAVGPGRETQ ATPESGKQTL
     KIFDGDDAVR RSQFRLVTVS RLAGAEEVLE AALRAHHIPE DPGHLELCRL PPSSQACDAW
     AGGKAGSAVI SEEGRSPGSG EATPEAWVIR ALPRAQEVLK IYPGWLKVGV AYVSVRVTPK
     STARSVVLEV LPLLGRQAES PESFQLVEVA MGCRHVQRTM LMDEQPLLDR LQDIRQMSVR
     QVSQTRFYVA ESRDVAPHVS LFVGGLPPGL SPEEYSSLLH EAGATKATVV SVSHIYSSQG
     AVVLDVACFA EAERLYMLLK DMAVRGRLLT ALVLPDLLHA KLPPDSCPLL VFVNPKSGGL
     KGRDLLCSFR KLLNPHQVFD LTNGGPLPGL HLFSQVPCFR VLVCGGDGTV GWVLGALEET
     RYRLACPEPS VAILPLGTGN DLGRVLRWGA GYSGEDPFSV LLSVDEADAV LMDRWTILLD
     AHEAGSAEND TADAEPPKIV QMSNYCGIGI DAELSLDFHQ AREEEPGKFT SRLHNKGVYV
     RVGLQKISHS RSLHKQIRLQ VERQEVELPS IEGLIFINIP SWGSGADLWG SDSDTRFEKP
     RMDDGLLEVV GVTGVVHMGQ VQGGLRSGIR IAQGSYFRVT LLKATPVQVD GEPWVQAPGH
     MIISAAGPKV HMLRKAKQKP RRAGTTRDAR ADAAPAPESD PR
//
